Research programme: neurological disorders therapeutics - Disarm Therapeutics

Drug Profile

Research programme: neurological disorders therapeutics - Disarm Therapeutics

Latest Information Update: 10 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Washington University
  • Developer Disarm Therapeutics
  • Class Antiglaucomas; Small molecules
  • Mechanism of Action Myeloid differentiation factor 88 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Amyotrophic lateral sclerosis; Glaucoma; Multiple sclerosis; Neurological disorders; Peripheral nervous system diseases

Most Recent Events

  • 19 Sep 2017 Disarm Therapeutics licensed IP covering SARM1 inhibitors from Washington University
  • 19 Sep 2017 Preclinical trials in Glaucoma in USA
  • 19 Sep 2017 Preclinical trials in Multiple sclerosis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top